Alphamab Oncology announced that Mr. XU Zhan Kevin ("Mr. Xu") has tendered his resignation from the position as a non-executive Director with effect from June 30, 2023 due to his other work commitments. Following his resignation as a non-executive Director, Mr. Xu has ceased to be a member of the strategy committee of the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.68 HKD | +0.37% |
|
-5.96% | -59.64% |
Jun. 05 | ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment | MT |
Jun. 05 | Alphamab Strikes Deal with Nasdaq-Listed ArriVent to Co-Develop Antibody Drug Conjugates | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-59.64% | 331M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- 9966 Stock
- News Alphamab Oncology
- Alphamab Oncology Resignation of Xu Zhan Kevin as Non-Executive Director and Member of the Strategy Committee